Pre Hospital Triage of Patients at Intermediate and High Risk for ACS

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCyril Camaro

About this trial

RESEARCH QUESTION: Is a treatment strategy that includes direct referral to a PCI center for intermediate to high-risk patients with non-ST elevation acute coronary syndrome (NSTE-ACS), both cost-effective and non-inferior for major adverse cardiac events (MACE)? HYPOTHESIS: Prehospital triage with the modified \[History-ECG-Age-Risk factors\] (HEAR) score and a high sensitivity (hs) point-of-care troponin (POCT) leads to a faster diagnosis of ACS, faster time to coronary angiography (CAG) and/or treatment with PCI, shorter length of stay, quicker availability of ambulances and more satisfaction and quality of life of patients. STUDY DESIGN: Randomized clinical trial. STUDY POPULATION: Patients ≥18 years with an intermediate to high risk for NSTE -ACS (defined as a modified HEAR score ≥ 4) INTERVENTION: applying modified HEAR score and hs POCT to identify patients for direct rule out (very low risk), transfer to the nearest hospital for rapid rule-out and/or fast-track diagnosis by CT coronary imaging (intermediate risk) or direct referral to a PCI center for CAG (high risk).

USUAL CARE/COMPARISON: Assessment of ACS at the nearest hospital. In case PCI is scheduled: transfer to nearest PCI center.

OUTCOME MEASURES: primary endpoints: healthcare costs and non-inferiority for MACE (all cause death, confirmed ACS, re ACS, and unplanned PCI or CABG) at 30 days. Secondary: MACE after rule out ACS at 30 days, Quality of life (EQ5D5L) and cost-effectiveness at 12 months.

SAMPLE SIZE: 1048 patients. COST-EFFECTIVENESS ANALYSIS / BIA: It is expected that the intervention group will reduce healthcare costs and potentially improve health-related quality of life in this target population. Cost-effectiveness will be expressed as cost per QALY gained. We assume a large potential saving more than € 37 million if 100% implemented. TIME SCHEDULE: 48 months; 36 month inclusion, follow-up 12 months

Eligibility criteria

Qualifiers

Age ≥ 18 years

All out-of-hospital patients with chest pain or symptoms suggestive of ACS with an indication for transfer to the (cardiac) emergency department to evaluate and rule out ACS

Modified HEAR(T) score ≥ 4

The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Disqualifiers

Electrocardiographic ST-segment elevation (STEMI)

Patients with confirmed myocardial infarction, PCI or CABG <14 days prior to inclu-sion

Patients presenting an obvious non-cardiac cause for the chest complaints who need evaluation at an emergency department, e.g. trauma, pneumothorax, sepsis, etc.

Patients in comatose state, defined as an EMV <8

Trial design

Treatments tested in this trial

  • Integrating the HEAR score and hs POC troponin into pre hospital triage decision-making:

Treatment groups

1,048 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Cyril Camaro

Lead sponsor

Radboud University Medical Center

Sponsor institution

Ambulance services Veiligheidsregio Gelderland-Zuid

Collaborator

Canisius-Wilhelmina Hospital

Collaborator

Slingeland Hospital

Collaborator

Maas Hospital Pantein

Collaborator

Rijnstate Hospital

Collaborator

RAV Brabant MWN

Collaborator